Merit Medical (MMSI) Surges Against Market Sell-Off on Medtronic Partnership

Merit Medical Systems (MMSI) is emerging as a rare bright spot in a sea of red during Thursday's trading session. While the S&P 500 is retreating 1.56%, MMSI has climbed 2.53% to reach $69.83. This move represents a significant 4.08% outperformance relative to the benchmark index, signaling strong idiosyncratic demand for the medical technology firm despite a broader risk-off sentiment in the markets.

Medtronic Partnership Ignites Recovery

The primary catalyst for this intraday surge is the market’s continued digestion of a major strategic milestone: an exclusive distribution agreement with Medtronic plc. Announced earlier this week, the deal grants Medtronic the rights to offer Merit’s newly FDA-cleared ViaVerte system. This system is a minimally invasive, implant-free basivertebral nerve ablation (BVNA) treatment designed for chronic vertebrogenic lower-back pain.

Investors are viewing this partnership as a major de-risking event for Merit’s endoscopy and spine portfolios. Medtronic’s vast distribution network and existing relationships with spine surgeons provide an immediate commercial runway for ViaVerte, which is expected to be available later this year. The agreement continues a long-standing relationship between the two companies, as Merit already supplies Medtronic with inflation syringes and steerable balloon catheters used in vertebral procedures.

Tapping into a High-Growth Market

The ViaVerte system is the first and only BVNA system featuring a physician-controlled steerable mechanism, allowing for precise targeting of the basivertebral nerve. This technology addresses a massive clinical need; the American Chronic Pain Association estimates that one in three Americans suffers from chronic pain. By partnering with Medtronic—a global leader in neuroscience and pain interventions—Merit is positioning itself to capture a significant share of the BVNA market, which is currently valued at approximately $200 million and growing at double-digit annual rates.

Rebound from 52-Week Lows

Today’s move is also technically significant. Prior to this week’s news, MMSI had been under pressure, recently touching a 52-week low near the $67.00 level. The stock’s ability to pivot and rally 2.53% on volume of 330.0K shares suggests that value seekers and institutional buyers are stepping in. Analysts at BTIG recently reiterated a Buy rating with a $107.00 price target, suggesting that even at today's $69.83 level, the stock remains significantly undervalued relative to its long-term growth prospects.

Needham analysts also maintained a Buy rating, noting that while the company’s recent guidance had been conservative, the Medtronic deal provides a clear catalyst for revenue acceleration in late 2026 and into 2027. The consensus price target among Wall Street analysts currently sits above $100.00, implying substantial upside from current levels.

Forward Outlook

As the trading session nears its close, MMSI’s resilience highlights a flight to quality within the healthcare technology space. Within the medical device sector, Merit is distinguishing itself through high-margin product launches, including its recently released Resilience Through-the-Scope Esophageal Stent. Investors are prioritizing companies with clear regulatory wins and established commercial partners, a trend that is likely to keep Merit Medical on the radar as the commercial rollout of ViaVerte begins in the coming months.